for people ages 18-80 (full criteria)
at La Jolla, California and other locations
study started
estimated completion



The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed prior 12-week induction study AMAN (NCT03518086).

Official Title

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)


Ulcerative Colitis Interleukin-23 (IL-23) IL-23p19 Inflammatory Bowel Disease Colitis Colitis, Ulcerative Ulcer Mirikizumab Mirikizumab Dose #1 Mirikizumab Dose #2


You can join if…

Open to people ages 18-80

  • Have completed Study AMAN (NCT03518086), with at least 1 study drug administration and without early termination of study drug.
  • Are willing and able to complete the scheduled study assessments, including endoscopy and daily diary entry.
  • If female, must meet the contraception requirements.

You CAN'T join if...

  • Participants diagnosed with Crohn's disease or inflammatory bowel disease-unclassified (indeterminate colitis) during the induction study AMAN (NCT03518086).
  • Participants with a bowel resection or other surgery for the treatment of UC during the previous induction study AMAN (NCT03518086), or are likely to require surgery for the treatment of UC during study AMBG.
  • Participants with evidence of colonic dysplasia or have been diagnosed with cancer of the gastrointestinal tract during study AMAN (NCT03518086).
  • Participants diagnosed with clinically important infection including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during the induction study AMAN (NCT03518086).
  • Participants who initiate a new prohibited medication during the induction study AMAN (NCT03518086).
  • Participants with certain laboratory abnormalities prior to start of AMBG that would require permanent discontinuation from study drug.


  • UC San Diego Altman Clinical and Translational Research Inst not yet accepting patients
    La Jolla California 92037 United States
  • University of California - San Diego not yet accepting patients
    La Jolla California 92093 United States
  • Clinical Applications Laboratories, Inc. accepting new patients
    San Diego California 92103 United States


accepting new patients
Start Date
Completion Date
Eli Lilly and Company
Phase 3
Study Type
Last Updated